论文部分内容阅读
目的:观察艾迪注射液联合化疗治疗老年非小细胞肺癌的临床疗效。方法:将60例患者随机分为两组,治疗组30例应用艾迪注射液联合PE方案化疗治疗,对照组单纯应用PE方案化疗并观察疗效。结果:治疗组与对照组总有效率分别为46.7%、40.0%(P>0.05)。而治疗组中位缓解期为7个月,对照组中位缓解期为5个月(P<0.05)。两组患者体重和karnofsky(KPS)评分,治疗组治疗后体重比治疗前增加(P<0.05),对照组治疗前后比较差异无显著性(P>0.05)。治疗组治疗后KPS评分比治疗增加(P<0.05),对照组治疗前后无明显变化(P>0.05)。毒副反应,白细胞下降Ⅲ～Ⅳ度治疗组为9例(30.0%),对照组为18例(60.0%);胃肠道反应Ⅰ～Ⅳ度治疗组14例(46.7%),对照组22例(73.3%),两组比较差异有显著性(P<0.05)。结论:艾迪注射液联合PE方案化疗能够提高机体免疫力,减轻化疗的毒副反应,增加体重;改善生活质量,延长生存期。
Objective: To observe the clinical efficacy of Aidi injection combined with chemotherapy in the treatment of elderly non-small cell lung cancer. Methods: Sixty patients were randomly divided into two groups. The treatment group was treated with Aidi Injection combined with PE regimen and the control group with PE regimen alone and the curative effect was observed. Results: The total effective rate of treatment group and control group were 46.7% and 40.0% (P> 0.05). The median response time was 7 months in the treatment group and 5 months in the control group (P <0.05). Body weight and karnofsky (KPS) scores of the two groups were significantly higher than those before treatment in the treatment group (P <0.05). There was no significant difference between before and after treatment in the control group (P> 0.05). The KPS score of the treatment group was higher than that of the treatment group (P <0.05), but there was no significant difference in the control group before and after treatment (P> 0.05). Toxicity and leukopenia in the treatment group were 9 (30.0%) in the treatment group Ⅲ and 18 (60.0%) in the control group, 14 (46.7%) in the treatment group Ⅰ ~ Ⅳ of the gastrointestinal reaction group, 22 Cases (73.3%), the difference between the two groups was significant (P <0.05). Conclusion: Aidi injection combined with PE regimen can improve immunity, reduce side effects of chemotherapy, increase body weight, improve quality of life and prolong survival.